Celldex Therapeutics to Present Data from the ReACT Study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting

HAMPTON, N.J., May 13, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq: CLDX ) announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The ReACT presentation will include final analysis of progression-free survival at 6 months (PFS6) and current data on overall survival and other endpoints. Data contained in the published abstract were from an analysis in October 2014. Data to be presented in the oral session will include comprehensive data from the study through March 2015.

  • Abstract #2009: Data from the ReACT study will be presented by David A. Reardon, M.D., in an oral presentation entitled " ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma " on Sunday, May 31, 2015 at 8:00 a.m. CDT. Dr. Reardon, Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Center; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, as well as the lead investigator of the ReACT study, will speak during the Clinical Science Symposium "Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data."  
  • Abstract #TPS1110: The Phase 2b METRIC study will be presented in a clinical trial in progress session as a poster entitled " METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC) " on Saturday, May 30, 2015 from 8:00 a.m. to 11:30 a.m.  
  • Abstract #TPS3105: Data from an investigator-sponsored, Phase 1/2 study of CDX-301, a potent hematopoietic cytokine that stimulates the expansion and differentiation of hematopoietic stem cells and dendritic cells, will be presented as a poster entitled " In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy " on Saturday, May 30, 2015 from 8:00 a.m. to 11:30 a.m.

RINTEGA® is a registered trademark of Celldex Therapeutics.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com .

Forward Looking Statement

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of RINTEGA® ("rindopepimut"; "rindo"; CDX-110), glembatumumab vedotin ("glemba"; CDX-011), varlilumab ("varli"; CDX-1127), CDX-1401, CDX-301 and other products and our goals for 2015. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of RINTEGA, glembatumumab vedotin and other drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Breakthrough Therapy Designation for RINTEGA, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: Sarah Cavanaugh, Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 Media Inquiries: Dan Budwick Pure Communications, Inc. (973) 271-6085

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mall of America Strives for World Record This Black Friday

Updated Category News Views 67

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 49

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 182

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 63

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 32

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 41

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading

Top 5 Most Recently Viewed Articles

Geleximco Group Partners with Leekr Technology for Innovation

Updated Category News Views 271

Introduction to a New Era of Collaboration Geleximco Group has recently established an exciting partnership with Leekr Technology, a prominent player in the intelligent chassis systems sector. This collaboration aims to significantly enhance the automotive manufacturing capabilities in the region. By leveraging their combined expertise, both companies are poised to make...

Continue Reading
Enerpac Tool Group's Earnings Preview and Stock Insights

Updated Category News Views 72

Enerpac Tool Group's Upcoming Earnings Announcement Enerpac Tool Group (NYSE: EPAC) is set to release its quarterly earnings report shortly. This announcement is pivotal for both current investors and those considering an investment in the company. With analysts predicting an earnings per share (EPS) of $0.53, excitement is building around whether Enerpac will meet or...

Continue Reading
Analyzing Rocket Lab's Options Activity for Investors

Updated Category News Views 185

Understanding Rocket Lab's Options Activity In recent trading, substantial bearish sentiment has emerged among investors of Rocket Lab (NASDAQ: RKLB), which should capture the attention of market observers. Tracking public options records reveals a significant uptick in activity, indicating that something potentially impactful could be on the horizon for the company....

Continue Reading
Greenway Health Collaborates with AWS to Innovate Healthcare

Updated Category News Views 284

Greenway Health Joins Forces with AWS Partner Network The collaboration enhances Greenway's ambulatory solutions and paves the way for full cloud migration. Advancing Healthcare Technology Greenway Health is excited to announce its membership in the Amazon Web Services (AWS) Partner Network (APN), marking a significant step in improving healthcare access and efficiency....

Continue Reading
Intel's Future Prospects: An Acquisition Target or Growth Story?

Updated Category News Views 335

Intel Corp: A New Chapter Amid Market Challenges Intel Corp (NASDAQ: INTC) experienced a notable uptick in stock value recently, spurred by reports suggesting that it may become an acquisition target. This news arrives as the semiconductor giant grapples with a significant decline in its stock price, which has dropped by approximately 54% over the past year. Speculative...

Continue Reading